Results 171 to 180 of about 79,802 (263)

Drug Critical Limits for Urgent Physician Notification

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 178-192, July 2026.
Critical limits represent quantitative decision thresholds for drugs that require immediate clinician notification and potential life‐saving intervention. United States hospitals lack a national standard for drug critical limits. We collected critical limits from 417 US hospitals across all 50 states and Washington, D.C.; of these, 411 maintained drug ...
Elina Kuang   +3 more
wiley   +1 more source

The Value and Challenges of Stakeholder Engagement in Rehabilitation Learning Health Systems: A Qualitative Pilot Study of Rehabilitation Directors

open access: yesLearning Health Systems, Volume 10, Issue 3, July 2026.
ABSTRACT Introduction Stakeholder engagement is a core element of a learning health system (LHS). Meaningful engagement of stakeholders can improve learning within a health system by informing program development and service delivery and by increasing buy‐in and sustainability of evidence‐based practices.
Nichole E. Stetten   +3 more
wiley   +1 more source

Prevalence and Correlates of Reporting a Gabapentin Prescription for Pain Among People Who Use Opioids: A Longitudinal Community‐Recruited Study

open access: yesDrug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Gabapentin is widely prescribed off‐label to treat pain. However, there are concerns about the proliferation of medical and non‐medical use, and the potential increased risk of overdose death associated with concurrent opioid use.
Evelyne Marie Piret   +7 more
wiley   +1 more source

Low-Intensity Focused Ultrasound Neuromodulation in Psychiatric Disorders: Mechanisms, Models, and Missing Links. [PDF]

open access: yesBiol Psychiatry
Arulpragasam AR   +7 more
europepmc   +1 more source

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6324-6333, July 2026.
ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy